• PDF: Delivered by email usually within 12 to 24 UK business hours.

ImmunoGen - Product Pipeline Review
Q4 2010

ImmunoGen - Product Pipeline Review Q4 2010

ImmunoGen - Product Pipeline Review - Q4 2010

Summary

Global Market Direct's pharmaceuticals report, "ImmunoGen - Product Pipeline Review - Q4 2010" provides data on the company's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. It also gives a complete picture of the company's future therapy areas of focus.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by Global Markets Direct's team of industry experts.

Scope

  • ImmunoGen - company overview including business description, key employees, and other facts.
  • Review of current pipeline of ImmunoGen human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, for the pharmaceutical markets across the globe.
  • Product profiles for late stage and clinical stage products of ImmunoGen with complete description of the product's developmental history, mechanism of action, clinical trials, major milestones and others.
  • Recent updates of the ImmunoGen's pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Evaluate ImmunoGen's strategic position with total access to a detailed intelligence on its product pipeline.
  • Assess the growth potential of ImmunoGen in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the ImmunoGen's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with ImmunoGen.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of ImmunoGen and identify potential opportunities in those areas.
  • Do deals with an understanding of the mergers and partnerships that have shaped the sector.
  • 1 Table of Contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Introduction
  • 3 ImmunoGen Snapshot
    • 3.1 Business Description
  • 4 ImmunoGen- Research and Development Overview
    • 4.1 Key Therapeutic Areas
  • 5 ImmunoGen- Pipeline Review
    • 5.1 Pipeline Products by Stage of Development
    • 5.2 Pipeline Products-Monotherapy
    • 5.3 Pipeline Products-Combination Treatment Modalities
  • 6 ImmunoGen Pipeline Products Glance
    • 6.1 ImmunoGen Phase II Pipeline
    • 6.2 ImmunoGen Phase I Pipeline
    • 6.3 ImmunoGen Pre-Clinical Pipeline
  • 7 ImmunoGen - Drug Profiles
    • 7.1 Product 1
    • 7.1.1 Product Description
    • 7.1.2 Mechanism of Action
    • 7.1.3 R&D Progress
  • 8 ImmunoGen Pipeline Analysis
    • 8.1 ImmunoGen Pipeline Products by Therapeutic Class
    • 8.2 ImmunoGen Pipeline Products by Target
    • 8.3 ImmunoGen Pipeline by Route of Administration
    • 8.4 ImmunoGen Pipeline Products by Molecule Type
  • 9 ImmunoGen- Recent Pipeline Updates
  • 10 ImmunoGen- Dormant Pipeline Projects
    • 10.1 Feature on Dormant Projects
  • 11 ImmunoGen- Discontinued Pipeline Products
    • 11.1 Discontinued Pipeline Product Profiles
    • 11.1.1 Product 1
  • 12 ImmunoGen - Featured News
  • 13 ImmunoGen Statement
    • 13.1 ImmunoGen - Locations and Subsidiaries
  • 14 Appendix
    • 14.1 Global Markets Direct Research Methodology
    • 14.2 Coverage
    • 14.3 Secondary Research
    • 14.4 Primary Research
    • 14.5 Models
    • 14.6 Expert Panels
    • 14.7 Contact Us
    • 14.8 Disclaimer
  • 1.1 List of Tables
    • Table 1: ImmunoGen - Key Information
    • Table 2: ImmunoGen - Key Facts
    • Table 3: ImmunoGen - Key Therapeutic Areas
    • Table 4: ImmunoGen - Pipeline by Stage of Development, 2010
    • Table 5: ImmunoGen - Monotherapy Products in Pipeline, 2010
    • Table 6: ImmunoGen - Combination Treatment Modalities in Pipeline, 2010
    • Table 7: ImmunoGen - Phase II Pipeline, 2010
    • Table 8: ImmunoGen - Phase I Pipeline, 2010
    • Table 9: ImmunoGen - Pre-Clinical Pipeline, 2010
    • Table 10: ImmunoGen - Pipeline By Therapeutic Class
    • Table 11: ImmunoGen - Pipeline By Target
    • Table 12: ImmunoGen - Pipeline By Route of Administration
    • Table 13: ImmunoGen - Pipeline By Molecule Type
    • Table 14: ImmunoGen - Recent Pipeline Updates
    • Table 15: ImmunoGen - Dormant Pipeline Projects
  • 1.2 List of Figures
    • Figure 1: ImmunoGen - Research and Development Overview
    • Figure 2: ImmunoGen - Pipeline by Stage of Development, 2010
    • Figure 3: ImmunoGen - Monotherapy Products in Pipeline, 2010
    • Figure 4: ImmunoGen - Combination Treatment Modalities in Pipeline, 2010
    • Figure 5: ImmunoGen - Pipeline By Therapeutic Class and Stage of Development
    • Figure 6: ImmunoGen - Pipeline By Therapeutic Class
    • Figure 7: ImmunoGen - Pipeline By Target and Stage of Development
    • Figure 8: ImmunoGen - Pipeline By Target
    • Figure 9: ImmunoGen - Pipeline By Route of Administration and Stage of Development
    • Figure 10: ImmunoGen - Pipeline By Route of Administration
    • Figure 11: ImmunoGen - Pipeline By Molecule Type and Stage of Development
    • Figure 12: ImmunoGen - Pipeline By Molecule Type
+44 20 8816 8548

Ask a question about ImmunoGen - Product Pipeline Review

Enter the characters you see in the picture below
Captcha